Amlodipine 2.5 mg Daily is Appropriate and Hydralazine Should Be Discontinued
For this 80-year-old patient with blood pressure now at 134/88 mmHg (down from 146/78 mmHg), switching from hydralazine 50 mg twice daily to amlodipine 2.5 mg daily is an excellent therapeutic decision that aligns with current guidelines and improves both safety and efficacy.
Why This Change Makes Sense
Current Blood Pressure Status
The patient's BP of 134/88 mmHg is at goal according to the 2024 ESC guidelines, which recommend targeting systolic BP of 120-129 mmHg in patients <85 years who tolerate treatment well 1. This patient is 80 years old and appears to be tolerating therapy, so the current BP is acceptable and may benefit from the more predictable control offered by amlodipine.
Problems with Hydralazine in This Context
Hydralazine is problematic for chronic outpatient hypertension management in elderly patients:
- Not a preferred agent: The 2017 ACC/AHA guidelines note that hydralazine's "unpredictability of response and prolonged duration of action do not make hydralazine a desirable first-line agent" 2
- Lupus-like syndrome risk: The FDA label warns that hydralazine can produce a clinical picture simulating systemic lupus erythematosus, including glomerulonephritis, with symptoms that may persist long after discontinuation 3
- Inappropriate for routine use: Recent evidence shows hydralazine is being overused for asymptomatic hypertension when scheduled antihypertensives would be more appropriate 4
Advantages of Amlodipine 2.5 mg in This Patient
Amlodipine is specifically recommended for elderly patients by the 2024 ESC guidelines, which state: "When initiating BP-lowering treatment for patients aged ≥85 years, and/or with moderate-to-severe frailty (at any age), long-acting dihydropyridine CCBs or RAS inhibitors should be considered" 1. At age 80, this patient falls into the category where dihydropyridine calcium channel blockers are preferred.
The 2.5 mg dose is ideal for elderly patients:
- The FDA label explicitly states that "elderly patients have decreased clearance of amlodipine with a resulting increase of AUC of approximately 40 to 60%, and a lower initial dose may be required" 5
- Multiple studies demonstrate efficacy of 2.5 mg in elderly hypertensives, with significant BP reductions (21-26/15-17 mmHg) and excellent tolerability 6, 7, 8
- The long half-life (35-50 hours) provides continuous 24-hour coverage and maintains BP control even if a dose is missed—critical for elderly patients who may have compliance issues 9
Safety profile in the elderly:
- Studies in patients ≥65 years show adverse event rates of only 18-24%, rated as mild to moderate, with tolerability rated as good or excellent 8
- No clinically significant effects on pulse rate, ECG, or body weight 10
- The 2.5 mg dose minimizes side effects like edema, which are more common at 10 mg 9
Implementation Strategy
- Discontinue hydralazine immediately - there is no need to taper this medication
- Start amlodipine 2.5 mg once daily - preferably in the morning based on evidence suggesting slight advantage over evening dosing 8
- Monitor BP after 2-4 weeks to assess response
- Screen for orthostatic hypotension before and after the medication change, as recommended by 2024 ESC guidelines: measure BP after sitting/lying for 5 minutes, then 1 and/or 3 minutes after standing 1
Key Monitoring Points
- Watch for peripheral edema (most common side effect, though less likely at 2.5 mg dose)
- Ensure BP remains controlled but not excessively low (avoid <120/70 mmHg to prevent hypoperfusion)
- If BP rises above 140/90 mmHg on follow-up, consider titrating to amlodipine 5 mg daily rather than restarting hydralazine
Bottom Line
This medication change represents guideline-concordant care that replaces an unpredictable, potentially harmful agent (hydralazine) with a well-studied, elderly-appropriate calcium channel blocker at an evidence-based starting dose. The current BP of 134/88 mmHg suggests adequate control that should be maintained or improved with amlodipine's more consistent pharmacokinetic profile.